Drug intelligence / Profile preview

disodium undecylenamido MEA-sulfosuccinate

Development stage
Unknown
Lead developer
Permamed
Modality
Small Molecules
Administration
Topical
01

Overview

Der-med (also known as Dermed) is a mild, lipid-replenishing skin wash lotion developed by Permamed. It is approved in Switzerland as a therapy-supporting treatment for various skin conditions, including psoriasis, eczema, ichthyosis, acne, and fungal skin infections (such as hand and foot mycoses). The active ingredient in Der-med is disodium undecylenamido MEA-sulfosuccinate, a mild anionic surfactant with disinfectant and antimicrobial properties that slightly inhibits the growth of bacteria and fungi. Formulated at a pH of 5.5, Der-med helps stabilize the skin's natural acid mantle, protects sensitive skin from dehydration, and supports the healing process of diseased skin. Additionally, Permamed markets a related product under the same brand family, Der-med dry skin lotion, which contains urea and polidocanol 600 for dry and itchy skin.

Brand names
Der-medDer-med Hautwaschlotion
Other names
disodium undecylenic monoethanolamide sulfosuccinatedisodium undecylenamido-MEA-sulfosuccinateundecylenamido MEA-sulfosuccinate disodium
02

Targets

Host skin barrier lipids and membranes

Beyond the preview

Go deeper on disodium undecylenamido MEA-sulfosuccinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on disodium undecylenamido MEA-sulfosuccinate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call